Select Medical Holdings (FRA:S24) Research & Development: €0 Mil (TTM As of Mar. 2026)


FRA:S24 Select Medical Holdings Corp FRA:S24
77 GF Score
Price €14.40
GF Value €14.99
! 7 Warning Signs
View Full Analysis

What is Select Medical Holdings Research & Development?

Select Medical Holdings FRA:S24 +1.41% 77 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates FRA:S24 with a GF Score™ of 77/100 and a GF Value™ of €14.99. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Select Medical Holdings's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Select Medical Holdings  (FRA:S24) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Select Medical Holdings Research & Development Related Terms

Select Medical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Select Medical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Select Medical Holdings Research & Development Chart

Select Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Select Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:S24
77GF Score
Select Medical Holdings Corp FRA:S24
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Select Medical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Select Medical Holdings (FRA:S24) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Select Medical Holdings and its competitors.
Is Select Medical Holdings' Research & Development too high?
Select Medical Holdings' current Research & Development is €0 Mil. Overall, Select Medical Holdings has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Select Medical Holdings' Research & Development compare to SGRY and MD?
Select Medical Holdings' Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Select Medical Holdings and its competitors. Select Medical Holdings's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Select Medical Holdings stock overvalued right now?
Select Medical Holdings (FRA:S24) has a current Research & Development of €0 Mil. The stock's GF Value™ is €14.99, compared to a current price of €14.40 — trading 3.9% below its estimated fair value. The current Research & Development is €0 Mil. Select Medical Holdings' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Select Medical Holdings (FRA:S24), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Select Medical Holdings (FRA:S24) Overvalued in 2026?

Based on GuruFocus' analysis, Select Medical Holdings stock appears to be undervalued. The current stock price of €14.40 is trading 3.9% below its estimated GF Value™ of €14.99.

Key valuation signals for FRA:S24:

  • Research & Development: €0 Mil
  • GF Value™: €14.99 vs. price of €14.40 (3.9% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the FRA:S24 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Select Medical Holdings Business Description

Other Exchanges SEM:USA
Address 4714 Gettysburg Road, P.O. Box 2034, Mechanicsburg, PA, USA, 17055
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
77GF Score

Get the complete analysis for FRA:S24

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.40
Price
€14.99
GF Value